



A guide to LUMAKRAS[®] prior authorizations (PAs)*

- The prescriber has identified the appropriate patient and prescribed LUMAKRAS[®]
- Considerations for collecting the appropriate information and documentation for the PA process

*Specific plan requirements may vary.

INDICATION

LUMAKRAS[®] is indicated for the treatment of adult patients with *KRAS* G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

Hepatotoxicity

- LUMAKRAS[®] can cause hepatotoxicity, which may lead to drug-induced liver injury and hepatitis.
- Among 357 patients who received LUMAKRAS[®] in CodeBreak 100, hepatotoxicity occurred in 1.7% (all grades) and 1.4% (Grade 3). A total of 18% of patients who received LUMAKRAS[®] had increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST); 6% were Grade 3 and 0.6% were Grade 4. In addition to dose interruption or reduction, 5% of patients received corticosteroids for the treatment of hepatotoxicity.
- Monitor liver function tests (ALT, AST, and total bilirubin) prior to the start of LUMAKRAS[®], every 3 weeks for the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop transaminase and/or bilirubin elevations.
- Withhold, dose-reduce, or permanently discontinue LUMAKRAS[®] based on severity of adverse reaction.

Please see full Important Safety Information on Page 4.

[Click here](#) for full Prescribing Information.

Your LUMAKRAS[®] patient's insurance may require a PA



Here are some considerations:

This resource may help you organize specific information about your patient's diagnosis and treatment history to complete a LUMAKRAS[®] PA.

Please note that PA criteria may vary by health plan, and be sure to confirm the PA criteria and documentation required by your patient's insurer.



Identify the correct diagnosis

- Primary and secondary ICD-10-CM diagnosis codes



Reference patient's previous and current treatment history from their chart

- Electronic medical records should indicate the current treatment, first-line treatments, and other current medications
- *KRAS* G12C diagnostic test or test result with dates (any test showing *KRAS* G12C mutation can be used)



Document prior therapy

- Patients must have received at least one systemic therapy prior to using LUMAKRAS[®]



Note: Documentation may be required by your patient's insurance. Make sure you read the PA criteria carefully and include all the necessary documents specifically required. Examples may include medical records, clinical chart notes, and claims histories.

TIP: If the patient has a previously approved LUMAKRAS[®] PA and the same insurance, make sure to start a PA Renewal or Reauthorization.

IMPORTANT SAFETY INFORMATION (Cont'd)

Interstitial Lung Disease (ILD)/Pneumonitis

- LUMAKRAS[®] can cause ILD/pneumonitis that can be fatal. Among 357 patients who received LUMAKRAS[®] in CodeBreak 100, ILD/ pneumonitis occurred in 0.8% of patients, all cases were Grade 3 or 4 at onset, and 1 case was fatal. LUMAKRAS[®] was discontinued due to ILD/pneumonitis in 0.6% of patients.
- Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, fever). Immediately withhold LUMAKRAS[®] in patients with suspected ILD/pneumonitis and permanently discontinue LUMAKRAS[®] if no other potential causes of ILD/pneumonitis are identified.

Please see full Important Safety Information on Page 4.

[Click here](#) for full Prescribing Information.



Identify the correct diagnosis

- Find the diagnosis the prescriber has documented in the chart notes and look for it on the PA
- If you don't see the patient's diagnosis on the PA, don't worry! Consult with the prescriber before you proceed since selecting the incorrect diagnosis may delay the approval

Diagnostic code example, ICD-10-CM codes:

C34.00 – C34.02 Malignant neoplasm of bronchus and lung; main bronchus

C34.10 – C34.12 Malignant neoplasm of bronchus and lung; upper lobe

C34.2 Malignant neoplasm of bronchus and lung; middle lobe

C34.30 – C34.32 Malignant neoplasm of bronchus and lung; lower lobe

C34.80 – C34.82 Malignant neoplasm of bronchus and lung; overlapping sites

C34.90 – C34.92 Malignant neoplasm of bronchus and lung; unspecified part

Codes identified above are provided as a courtesy only and are not comprehensive or instructive. Coding and coverage policies can change without warning. The healthcare provider is solely responsible for determining coverage, coding, and reimbursement. Amgen does not guarantee coverage or reimbursement. Please check with the payer to verify codes and special billing requirements.



Reference patient's previous and current treatment history from their chart

- Patients will need to have completed previous therapy for locally advanced or metastatic NSCLC
- Patients will need to have a documented *KRAS* mutation

Diagnostic test example, *KRAS* test CPT codes:

Single gene: 81275 and 81276

NGS: 81445, 81456, and 81479



Document prior therapy

- Patient medical/treatment history
- Previous therapies used to treat the patient
- Relevant biomarker test results
- Clinical rationale documenting medical necessity for treatment

Some payers may require additional information or documentation. Along with the information listed, the criteria could include:

- **Documented disease progression** on one prior therapy
- **Medical reason** why a patient cannot start or remain on a different therapy
 - Drug interactions
 - Adverse event risk profile
 - Patients that have specific dosing and/or administration requirements
- **Confirmation** that LUMAKRAS® is being used as monotherapy

ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; CPT= Current Procedural Terminology; NGS=next-generation sequencing.

IMPORTANT SAFETY INFORMATION (Cont'd)

Most Common Adverse Reactions

- The most common adverse reactions $\geq 20\%$ were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough.

Please see full Important Safety Information on Page 4.
[Click here](#) for full Prescribing Information.





An Amgen® Access Specialist can provide coverage and access resources to support your patients, such as:

- Help with navigating PA appeals and fulfillment processes
- Educating on payer requirements and necessary documentation for individual patient support

Learn more at AmgenSupportPlus.com

IMPORTANT SAFETY INFORMATION

Hepatotoxicity

- LUMAKRAS® can cause hepatotoxicity, which may lead to drug-induced liver injury and hepatitis.
- Among 357 patients who received LUMAKRAS® in CodeBreak 100, hepatotoxicity occurred in 1.7% (all grades) and 1.4% (grade 3). A total of 18% of patients who received LUMAKRAS® had increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST); 6% were grade 3 and 0.6% were grade 4. In addition to dose interruption or reduction, 5% of patients received corticosteroids for the treatment of hepatotoxicity.
- Monitor liver function tests (ALT, AST, and total bilirubin) prior to the start of LUMAKRAS®, every 3 weeks for the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop transaminase and/or bilirubin elevations.
- Withhold, dose reduce, or permanently discontinue LUMAKRAS® based on severity of adverse reaction.

Interstitial Lung Disease (ILD)/Pneumonitis

- LUMAKRAS® can cause ILD/pneumonitis that can be fatal. Among 357 patients who received LUMAKRAS® in CodeBreak 100 ILD/pneumonitis occurred in 0.8% of patients, all cases were grade 3 or 4 at onset, and 1 case was fatal. LUMAKRAS® was discontinued due to ILD/pneumonitis in 0.6% of patients.
- Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, fever). Immediately withhold LUMAKRAS® in patients with suspected ILD/pneumonitis and permanently discontinue LUMAKRAS® if no other potential causes of ILD/pneumonitis are identified.

Most Common Adverse Reactions

- The most common adverse reactions ≥ 20% were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough.

Drug Interactions

- Advise patients to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, dietary and herbal products.
- Inform patients to avoid proton pump inhibitors and H₂ receptor antagonists while taking LUMAKRAS®.
- If coadministration with an acid-reducing agent cannot be avoided, inform patients to take LUMAKRAS® 4 hours before or 10 hours after a locally acting antacid.

[Click here](#) for LUMAKRAS® full Prescribing Information.

REFERENCE

LUMAKRAS® (sotorasib) prescribing information, Amgen.



© 2024 Amgen® Inc. All rights reserved.
USA-510-81713 05/24

